From Seekingalpha · Edmund Ingham · · 30s
Moderna Cancer Vaccine Data Leak
Moderna's cancer vaccine data leak reveals mixed results for melanoma treatment.
In brief
Moderna's cancer vaccine data leak reveals mixed results for melanoma treatment. Moderna's personalized cancer vaccine shows 42% reduced recurrence risk but lacks long-term efficacy data. Originally reported by Seekingalpha.
Moderna Shares Drop
Moderna's stock fell 20% to $182 per share after early data on its personalized cancer vaccine.
42% Recurrence Reduction
Intismeran plus Keytruda showed a 42% reduction in recurrence or death risk versus Keytruda alone.
Key Uncertainties Remain
Durability, overall survival, and commercial viability remain uncertain with over half of patients not responding.
The main idea
Moderna's personalized cancer vaccine shows 42% reduced recurrence risk but lacks long-term efficacy data.
